TNFRSF1A and multiple sclerosis: These findings provide supporting evidence in favour of TNFR1 blockade in vivo, in diseases in which TNFR1 signalling has been shown to play the dominant role in pathogenesis, such as inflammatory arthritis and multiple sclerosis [8, 27].